"First I’ll lose the weight, and then I’ll start exercising."
It is a thought shared by almost anyone starting highly effective obesity medications like Wegovy or Mounjaro. The intuitive assumption is that as the pounds come off and the body feels lighter, physical movement will naturally increase.
However, real-world data reveals the exact opposite. Among individuals prescribed GLP-1 receptor agonists, daily step counts actually declined compared to their activity levels before starting the medication.
Counterintuitive Results From Wearable Data
The findings were presented by a research team led by Dr. Sajana Maharjan of HSHS St. John’s Hospital in Springfield, Illinois, at the Endocrine Society’s annual meeting (ENDO 2026) in Chicago.
Unlike past research that relied on self-reported patient surveys—which are often skewed by memory lapses—this study utilized objective data from the National Institutes of Health’s (NIH) All of Us Research Program. The program links participants’ electronic medical records directly with real-time tracking from Fitbit wearable devices.
Of the 1,950 adults with obesity who newly initiated GLP-1 therapy, the researchers analyzed 753 individuals who maintained sufficient Fitbit records. The cohort had an average age of 52.7 years, and 78.6% were women. Within this group, 81.9% of participants suffered from musculoskeletal pain, 67.3% had hypertension, and 48.1% had Type 2 diabetes.
According to the Endocrine Society, this marks the first large-scale study to leverage wearable-device data to track actual physical behavioral changes in GLP-1 users.
The results quantified a distinct drop in daily movement. Average daily step counts fell by 560 steps, dropping from 5,047 steps per day before treatment to 4,487 steps after initiation. Time spent in moderate-to-vigorous physical activity (MVPA) experienced a corresponding decline, sliding from 28 minutes down to 22 minutes per day. The analysis spanned several common GLP-1 class medications, including semaglutide (Wegovy, Ozempic), liraglutide (Saxenda), dulaglutide, and tirzepatide (Mounjaro, Zepbound).
While the data proved that weight loss does not automatically trigger an uptick in physical activity, the authors noted that the study was observational and did not establish a direct causal mechanism.
The Unanswered Question: Why Does Activity Decline?
The study clearly mapped how much physical activity decreased, but it left the question of why open for investigation. The steepest declines were concentrated among male participants and individuals with pre-existing joint or muscle pain. Conversely, factors like age, a history of heart failure, or prior stroke had no significant impact on the downward trend.
While the exact causes require further clinical study, the data points to a few likely culprits. First, pain and fatigue are significant barriers; because more than 80% of the cohort experienced musculoskeletal pain, movement may have been physically restrictive.
Additionally, GLP-1 medications are known to induce side effects that suppress not only appetite but also overall energy levels. When individuals experience systemic fatigue during rapid weight loss, structured exercise can easily transition from a healthy daily habit into an exhausting chore. The study did not explicitly test fatigue or explain why men experienced a sharper decline; these remain strong clinical inferences drawn from the data.
The High Stakes of Muscle Loss
These behavioral trends carry major implications for long-term health. Weight loss driven by GLP-1 receptor agonists is rarely limited to body fat alone; without physical intervention, the body naturally sheds vital lean muscle mass alongside adipose tissue.
If a patient's daily activity drops concurrently with rapid weight loss, the downward trend on the scale may mask a dangerous, accelerated loss of muscle architecture. Consistent physical activity—particularly resistance training—is the primary clinical tool to mitigate muscle wasting and preserve metabolic strength.
"Our study reinforces that exercise cannot be optional for people taking these medications," noted Dr. Maharjan. "We need targeted interventions that actively encourage physical activity alongside obesity prescriptions."
Prescribing Exercise Alongside Medication
Ultimately, the study underscores a vital truth: weight-loss medications cannot serve as a standalone solution. While drugs like Wegovy and Mounjaro excel at curbing appetite and lowering body weight, they cannot replace the metabolic and cardiovascular benefits of physical movement. From the first day a GLP-1 is prescribed, patients must consciously design a lifestyle framework that keeps them moving.
Medical experts emphasize that consistency is far more critical than extreme intensity. A standard clinical baseline recommends 30 minutes of moderate activity, five days a week. This does not require an elite gym membership; brisk walking is highly effective, and the time can easily be broken down into manageable 10-minute intervals throughout the day. To fully protect muscle tissue, however, incorporating basic strength training alongside aerobic walking remains the gold standard.
For those currently taking a GLP-1 medication, a falling number on the scale should not invite complacency. It is a signal to proactively protect the muscle tissue beneath. Rather than viewing weight loss as a reason to rest, patients must treat their lighter bodies as an opportunity to move more.
